Longevity Peptides: Evidence and Regulatory Status
An evidence review of epithalon, MOTS-c, elamipretide, humanin, and 5-Amino-1MQ, including elamipretide's specific Barth syndrome approval.
Several compounds are marketed together as a “longevity stack,” but no trial shows that their combination delays aging, extends human life, or prevents age-related disease. The substances differ substantially in chemistry and evidence. 5-Amino-1MQ is a small molecule, not a peptide.
Evidence by compound
| Compound | Established or studied context | Limit for a longevity claim |
|---|---|---|
| Epithalon | Laboratory and limited human research | Telomere-related mechanisms do not establish longer life or a validated preventive regimen. |
| MOTS-c | Predominantly preclinical mitochondrial and metabolic research | Animal effects do not establish clinical benefit in healthy adults. |
| SS-31 (elamipretide) | FDA accelerated approval in September 2025 as Forzinity to improve muscle strength in people with Barth syndrome who weigh at least 30 kg | This is a specific rare-disease indication, not approval for aging prevention. Confirmatory clinical benefit is still required. |
| Humanin | Laboratory and animal research | Clinical efficacy and safety for longevity have not been established. |
| 5-Amino-1MQ | Preclinical NNMT-inhibitor research | No human longevity outcome has been demonstrated. |
The FDA approval announcement and Forzinity label describe a defined formulation, population, and indication for elamipretide. Those instructions cannot be converted into an off-label multi-compound “longevity cycle.”
Why the combination remains unproven
Mitochondrial signaling, telomeres, and cellular stress responses are legitimate research topics. Measuring a pathway in cells is not the same as showing fewer diseases or longer life in people. There are no controlled human data defining the combined benefits, interactions, route, or schedule of these agents. Even a medicine approved for Barth syndrome needs its benefit and risks evaluated in any new population.
Useful research would measure clinically meaningful outcomes, include a comparator, and track adverse events over a suitable period. Until then, specific administration schedules and claims of synergy for this combination are not evidence-based.
References
Healing Peptide Combinations: What the Evidence Supports
An evidence review of BPC-157, TB-500, GHK-Cu, and thymosin alpha-1 for tissue repair, with limits of animal and human research.
Metabolic Peptide Combinations: An Evidence Review
What human trials show for semaglutide and tesamorelin, what remains preclinical for AOD-9604 and 5-Amino-1MQ, and why their combination is untested.